Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
Emrelis becomes the first drug for cMet-positive NSCLC, but only for the highest expressers.
The company deprioritises its lead project, naporafenib, shifting to two Joyo-originated assets.
IBI3020 beats Chengdu Kanghong's KH815 into clinical trials.
GSK and iTeos dump belrestotug, with the latter now looking at “strategic alternatives”.
The group’s point-of-care Car-T push looks to have stalled.
After earlier masked probody setbacks, CytomX surprises with CX-2051.
